MoonLake Immunotherapeutics (MLTX) Capital Expenditures (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Capital Expenditures of $35000.0 for Q1 2025, down 80.11% quarter-over-quarter from $176000.0 in Q4 2024.
MoonLake Immunotherapeutics (MLTX) Capital Expenditures (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $35000.0 for Q1 2025.
- In Q1 2025, Capital Expenditures changed N/A year-over-year to $35000.0; the TTM figure through Dec 2025 stood at $35000.0 (down 93.27% YoY), while the FY2025 annual figure was $35000.0, down 93.27% from the prior year.
- Capital Expenditures for Q1 2025 stood at $35000.0, down from $176000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $344000.0 in Q3 2024, with the low at -$2.0 in Q2 2022.
- The 4-year median for Capital Expenditures is $32376.0 (2021), against an average of $81433.9.
- Peak annual rise in Capital Expenditures reached 100.0% in 2022, while the deepest fall reached 100.0% in 2022.
- MoonLake Immunotherapeutics' Capital Expenditures stood at $50710.0 in 2021, then slumped by 100.0% to $1.0 in 2022, then surged by 17599900.0% to $176000.0 in 2024, then plunged by 80.11% to $35000.0 in 2025.
- Business Quant data shows MLTX's Capital Expenditures at $35000.0 in Q1 2025, $176000.0 in Q4 2024, and $344000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Sep 30, 2025 | -1.11 Mn |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 176,000.00 |
| Dec 31, 2024 | 176,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Dec 31, 2022 | 1.00 |
| Dec 31, 2022 | 1.00 |
| Jun 30, 2022 | -2.00 |
| Jun 30, 2022 | -2.00 |
| Mar 31, 2022 | 16,010.00 |
| Mar 31, 2022 | 16,010.00 |